Efficacy and Safety of Tirzepatide for Weight Management

What Was Tested

In this phase 3 trial, researchers set out to test Tirzepatide.

It will include adults in Bangladesh who are overweight or obese, with or without type 2 diabetes.

The main questions it aims to answer are: Does tirzepatide help people lose weight?

It had 1 arm (groups): Tirzepatide arm (experimental).

The registry classes the interventions as drug.

More on the Plan

While lifestyle modifications, such as adhering to a low-calorie diet and enhancing physical activity, remain the cornerstone of obesity management, the recent development of anti-obesity medications such as GLP-1 agonists has transformed treatment options.

The follow-up period will be 52 weeks (12 months) from the start of treatment.

The study will also evaluate the incidence and severity of adverse events, alongside physical examination results, blood pressure measurements, and laboratory parameter changes from baseline.

Adhering to Good Clinical Practice Guidelines, this study will follow ethical principles outlined in the Declaration of Helsinki.

Who Took Part

Enrollment: 440 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Informed consent will be obtained before any trial-related activities. Male or female, aged ≥18 years at the time of signing the informed consent form. Have a history of at least one self-reported unsuccessful dietary effort to lose body weight. Body mass index (BMI):. ≥30 kg/m² with or without any weight-related comorbidities or.

The full record lists 29 inclusion and 22 exclusion criteria; among the exclusions: treatment with any medication for the indication of obesity within the past 90 days before screening (e.g., orlistat, liraglutide, naltrexone/bupropion, diethylpropion, phendimetrazine, semaglutide, and setmelanotide); any previous obesity treatment with surgery or a weight loss device during a lifetime; have started implantable or injectable contraceptives (such as depo-provera®) within 18 months prior to screening.

How the Study Was Run

It was run as a single-group and open-label study.

Everyone knew when Tirzepatide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2025-01-01 with completion listed for 2026-06-30.

It ran at 1 site in Bangladesh.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Change in body weight (kg) (time frame: 52 weeks).

It also tracked 11 secondary outcomes, for example Change in BMI, Change in Waist circumference, Change in HbA1c, Change in fasting plasma glucose, Change in blood pressure and Change in lipid profile.

What This Means in Plain Language

Put simply, this is a phase 3 trial of Tirzepatide in 440 people.

Its status is active not recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page, all human trials.